Napsagatran is a novel, selective thrombin inhibitor used for its anticoagulant effects; it prolongs activated partial thromboplastin time (aPTT) and prothrombin time (PT) in a dose-dependent manner; reduces time to reperfusion and delays or prevents reocclusion; and significantly inhibits thrombus growth by reducing fibrinogen incorporation into thrombi.